The need for wider accessibility, equity, and affordability are significant factors to consider for advancement of these BiTE therapies.
October II, 2023
The role of risk stratification in treatment decisions for patients with newly diagnosed, transplant eligible multiple myeloma vs newly diagnosed, transplant ineligible multiple myeloma was explored by Natalie S. Callander, MD.
Allogeneic transplant is, today, a curative therapy for a variety of blood cancers, including many cases of acute monocytic leukemia, acute lymphoblastic leukemia, and myelodysplastic syndromes.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
